Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-28 | Dr. Kewalramani is our Chief Executive Officer and President and became a member of our Board of Directors on February 13, 2020. She was our Executive Vice President and Chief Medical Officer from April 2018 through March 2020. She was our Senior Vice President, Late Development from February 2017 until April 2018. |
| 2021-04-08 | Dr. Kewalramani has been our Chief Executive Officer and President since April 2020 and a member of our board since February 2020. Dr. Kewalramani was our Executive Vice President and Chief Medical Officer from April 2018 through March 2020. She was our Senior Vice President, Late Development from February 2017 until April 2018. From August 2004 to January 2017, she served in roles of increasing responsibility at Amgen Inc., most recently as Vice President, Global Clinical Development, Nephrology & Metabolic Therapeutic Area and as Vice President, U.S. Medical Organization. From 2014 through 2019, Dr. Kewalramani was the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee. She completed her internship and residency in Internal Medicine at the Massachusetts General Hospital and her fellowship in Nephrology at the Massachusetts General Hospital and Brigham and Women’s Hospital combined program. Dr. Kewalramani holds a B.A. from Boston University and an M.D. from Boston University School of Medicine. Dr. Kewalramani also completed the General Management Program at Harvard Business School and is an alumnus of the school. |
| 2022-04-07 | Reshma Kewalramani, M.D. Chief Executive Officer and President |
| 2023-04-06 | Dr. Kewalramani CEO and President of Vertex Pharmaceuticals Incorporated since April 2020. ... 2022 Total Compensation: $15,864,497. |
| 2024-04-04 | Reshma Kewalramani CEO and President Age 51 Director Since 2020 Board Committees: None 2023 Compensation: $20,594,441 Dr. Kewalramani possesses strong leadership qualities, significant experience overseeing and scaling the operations of a global enterprise, deep expertise in drug development, and wide-ranging experience in policy matters, demonstrated through her services as a senior executive in the biotechnology sector. |
| 2025-04-03 | Dr. Kewalramani is Chief Executive Officer and President of Vertex Pharmaceuticals Incorporated since April 2020. She possesses strong leadership qualities, significant experience overseeing and scaling the operations of a global enterprise, deep expertise in drug development, and wide-ranging experience in policy matters, demonstrated through her services as a senior executive in the biotechnology sector. Dr. Kewalramani’s 2024 total compensation was $21,538,668. |
Data sourced from SEC filings. Last updated: 2026-02-03